Confusion over whether new technologies should be regulated at European or state levelBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7070.1486c (Published 07 December 1996) Cite this as: BMJ 1996;313:1486
- Frederic Fleurette
- Head, health technology assessment programme Agence Nationale pour le Developpement de l'Evaluation Medicale, 159 rue Nationale, 75013 Paris, France
EDITOR,—In their editorial on the Safety and Efficacy Register of New Interventional Procedures, Trevor A Sheldon and Alex Faulkner discuss regulation of the new health technologies.1 It is true that, if drugs have to be evaluated before their widespread use is permitted, one could expect the same requirement for interventional technologies and that, because this has not been the case, new technologies have diffused through health care systems despite lack of evidence of their safety, effectiveness, and cost effectiveness.
The creation of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial